is tirzepatide a glp-1 receptor agonist Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology Renal effects of GLP-1 receptor

In both mice and humans, glucagon administration enhances energy expenditure and suppresses food ...

Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors

Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios

However, renal effects of GLP-1 in heart failure (HF) has not been elucidated

Once Monthly GLP-1 Maridebart cafraglutide is an investigational once-monthly injectable drug developed by Amgen that shows significant promise for treating obesity and Type 2 diabetes

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes